Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

ELYM 10.11.2024

Full Press ReleaseSEC FilingsOur ELYM Tweets

About Gravity Analytica

Recent News

  • 01.09.2025 - Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
  • 12.19.2024 - Climb Bio to be Added to the Nasdaq Biotechnology Index
  • 12.03.2024 - December 3, 2024 - December 5, 2024 : 36th Annual Piper Sandler Healthcare Conference

Recent Filings

  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 8-K Current report

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.

Poster Presentation

A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous NephropathyPresenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glomerular Center;Chief, Division of Nephrology, St. Peter's Hospital; Chief, Clinical Research, St. Peter's Health Partners;Clinical Scientist, Massachusetts General HospitalSession Title: Membranous Nephropathy, FSGS, and Minimal Change Disease [PO1402-1]Session Date, Time: October 24, 2024 from 10:00 a.m. to 12:00 p.m. PTPoster Board #: TH-PO587

About Climb Bio, Inc.Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visitclimbbio.com.

InvestorsChris BrinzeyICR Westwicke339-970-2843

MediaJon YuICR Westwickejon.yu@westwicke.com475-395-5375

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com